Glucotrack completes 1:20 reverse stock split; first human CBGM study successful with no serious adverse events

Glucotrack, Inc.

Effective Feb 3, 2025, every 20 pre-split shares combined into 1 share; outstanding shares reduced from ~155.5M to ~7.8M.
First in-human CBGM study met primary endpoint: no procedure- or device-related serious adverse events from implant through 7 days post-removal.
Six participants with diabetes mellitus; CBGM sensor lead placed intravascularly in subclavian vein for 4-day in-hospital monitoring.
Study confirmed CBGM sensor lead function; system accuracy consistent with prior animal studies; next step is long-term clinical trials.
Ticker GCTK unchanged; new CUSIP 45824Q705; shares trade on split-adjusted basis from Feb 4, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.